Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting

Cellular immunotherapy, including the chimeric antigen receptor T (CAR-T) cell therapy and CAR- natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation and development in recent years. CAR-T cell therapy is now emerging as a powerful cancer therapy with enormous potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ji-nuo, Gu, Tianning, Hu, Yongxian, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508791/
https://www.ncbi.nlm.nih.gov/pubmed/36153595
http://dx.doi.org/10.1186/s40164-022-00316-8
_version_ 1784797095228604416
author Wang, Ji-nuo
Gu, Tianning
Hu, Yongxian
Huang, He
author_facet Wang, Ji-nuo
Gu, Tianning
Hu, Yongxian
Huang, He
author_sort Wang, Ji-nuo
collection PubMed
description Cellular immunotherapy, including the chimeric antigen receptor T (CAR-T) cell therapy and CAR- natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation and development in recent years. CAR-T cell therapy is now emerging as a powerful cancer therapy with enormous potential, demonstrating impressive anti-tumor activity in the treatment of hematological malignancies. At the 2021 ASH annual meeting, numerous breakthroughs were reported concerning acute lymphocytic leukemia (ALL), lymphoma, acute myeloid leukemia (AML), and multiple myeloma (MM). Universal CAR-T cell and CAR-NK cell therapy, as well as induced pluripotent stem cell (iPSC)-derived immunotherapy, offer great “off-the-shelf” benefits. Major development and updates of cellular immunotherapy for hematological malignancies reported at the 2021 ASH annual meeting are summarized in this review.
format Online
Article
Text
id pubmed-9508791
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95087912022-09-25 Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting Wang, Ji-nuo Gu, Tianning Hu, Yongxian Huang, He Exp Hematol Oncol Review Cellular immunotherapy, including the chimeric antigen receptor T (CAR-T) cell therapy and CAR- natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation and development in recent years. CAR-T cell therapy is now emerging as a powerful cancer therapy with enormous potential, demonstrating impressive anti-tumor activity in the treatment of hematological malignancies. At the 2021 ASH annual meeting, numerous breakthroughs were reported concerning acute lymphocytic leukemia (ALL), lymphoma, acute myeloid leukemia (AML), and multiple myeloma (MM). Universal CAR-T cell and CAR-NK cell therapy, as well as induced pluripotent stem cell (iPSC)-derived immunotherapy, offer great “off-the-shelf” benefits. Major development and updates of cellular immunotherapy for hematological malignancies reported at the 2021 ASH annual meeting are summarized in this review. BioMed Central 2022-09-24 /pmc/articles/PMC9508791/ /pubmed/36153595 http://dx.doi.org/10.1186/s40164-022-00316-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Wang, Ji-nuo
Gu, Tianning
Hu, Yongxian
Huang, He
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
title Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
title_full Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
title_fullStr Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
title_full_unstemmed Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
title_short Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
title_sort novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ash annual meeting
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508791/
https://www.ncbi.nlm.nih.gov/pubmed/36153595
http://dx.doi.org/10.1186/s40164-022-00316-8
work_keys_str_mv AT wangjinuo novelcellularimmunotherapiesforhematologicalmalignanciesrecentupdatesfromthe2021ashannualmeeting
AT gutianning novelcellularimmunotherapiesforhematologicalmalignanciesrecentupdatesfromthe2021ashannualmeeting
AT huyongxian novelcellularimmunotherapiesforhematologicalmalignanciesrecentupdatesfromthe2021ashannualmeeting
AT huanghe novelcellularimmunotherapiesforhematologicalmalignanciesrecentupdatesfromthe2021ashannualmeeting

Ejemplares similares